Hernandez-Baldizon Samuel
Servicio de Reumatología, Hospital de Cruces, Baracaldo, Vizcaya, España.
Reumatol Clin. 2012 Jan-Feb;8(1):42-5. doi: 10.1016/j.reuma.2011.01.010. Epub 2011 Sep 25.
Methotrexate (MTX) is the first choice disease modifying anti-rheumatic drugs for rheumatoid arthritis. In spite of its generalized use by rheumatologists worldwide, there is a general lack of agreement regarding the route of administration, the start-up dose and the way to increase the same. In this article we propose a simplified outline for the use of the drug that should be individualized, based on it's pharmacological aspects, guidelines and recommendations published in high impact factor journals during the past few years. Adverse reactions and side effects, as well as their follow up are also reviewed.
甲氨蝶呤(MTX)是类风湿关节炎改善病情抗风湿药物的首选。尽管全球风湿病学家普遍使用该药物,但在给药途径、起始剂量以及增加剂量的方式上,仍普遍缺乏共识。在本文中,我们根据过去几年发表在高影响因子期刊上的药理学方面、指南和建议,提出了一个应个体化使用该药物的简化概述。还对不良反应和副作用及其后续处理进行了综述。